Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
Open accessThe DOI matches its Crossref record.
Abstract
Sunitinib, a multitargeted tyrosine-kinase inhibitor, extends survival of patients with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumours. Between October 2005 and March 2007, we retrospectively reviewed blood glucose level variations associated with sunitinib therapy in patients treated for mRCC. Nineteen of the patients had type II diabetes. All 19 patients had a decrease in blood glucose level (mean 1.77 mmol l(-1)) after 4 weeks of treatment. This was followed by re-elevation in the 2-week rest period. After two cycles of sunitinib administration, two patients had stopped blood glucose-lowering drugs whereas five other patients had normalised their blood glucose level. On the basis of pre-clinical data, we hypothesise that several mechanisms could be involved in this process, such as capillary regression of pancreatic islets, IGF-1 modulation through HIF1-alpha or NF-kappaB activation. In addition, a decrease of glucose uptake in the context of concomitant gastrointestinal toxicity cannot be excluded. Glycaemic control should be carefully evaluated in diabetic patients treated with sunitinib, and routine monitoring is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Approach to the Patient: Insulinoma
Hofland, J., Refardt, J. C., Feelders, R. A., Christ, E., & de Herder, W. W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad641 · Cited by 91
Chen, J., Wang, C., Han, J., Luan, Y., Cui, Y., Shen, R., Sha, D., Cong, L., Zhang, Z., & Wang, W. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.45 · Cited by 37
Sunitinib Specifically Augments Glucose-Induced Insulin Secretion
Lutz, S. Z., Ullrich, A., Häring, H.-U., Ullrich, S., & Gerst, F. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.04.018 · Cited by 24
The Early Effect of Sunitinib on Insulin Clearance in Patients with Metastatic Renal Cell Carcinoma
Thijs, A. M. J., Tack, C. J., van der Graaf, W. T. A., Rongen, G. A., & van Herpen, C. M. L. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12797 · Cited by 5
Metadata
- Authors
- Billemont, B., Medioni, J., Taillade, L., Helley, D., Meric, J. B., Rixe, O., & Oudard, S.
- Venue
- British Journal of Cancer
- Published
- 2008-10-07
- Volume
- 99
- Issue
- 9
- Pages
- 1380-1382
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2070009707
- Cited by
- 73
- References
- 0
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. https://app.cochat.ai/papers/10.1038/sj.bjc.6604709
- The paper
- Billemont, B., Medioni, J., Taillade, L., Helley, D., Meric, J. B., Rixe, O., & Oudard, S. (2008). Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604709
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.